Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World March 7, 2008 Peter Mitchell	Uk Drug Pricing System Scrapped The UK government is scrapping its existing national scheme for controlling drug prices. The system, called the Pharmaceutical price regulation scheme (PPRS), will be replaced by a newly negotiated agreement on 1 September 2008.
Pharmaceutical Executive May 1, 2011 Julian Upton	UK Stakeholders Have Their Say on Value-Based Pricing The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance.
Chemistry World June 18, 2008 Ananyo Bhattacharya	Deal on NHS drugs set to trim pharma profits An agreement between the UK government and the pharmaceutical industry will cut around five per cent off the cost of medicines sold to the National Health Service
Pharmaceutical Executive May 1, 2012	Value-Based Pricing: Too High a Price for UK Pharma? Changes to the system in the UK could finally put some real metrics behind the elusive concept of value but with payers clearly in the driver's seat, who needs clarity?
Pharmaceutical Executive August 1, 2008 Sarah Houlton	Jumping the Gun The Association of the British Pharmaceutical Industry and the British government have come up with a solution for price regulation that isn't as bad as the industry had feared.
Chemistry World April 2007 Richard Barker	Comment: Pricing Pills An Office of Fair Trading report claims The UK's National Health Service is paying over the odds for its drugs, but this is not so. Medicine prices are 21% lower in real terms than ten years ago.
Chemistry World March 20, 2008 Richard Van Noorden	UK Drug Firms to Slash Research and Jobs The UK pharmaceutical industry is expecting to cut jobs and investment in R&D following an alarming slump in confidence in the UK market.
Chemistry World November 21, 2008 Pete Mitchell	UK drug price deal finalised The new deal is guaranteed to continue for five years - a great relief to the industry.
Pharmaceutical Executive August 1, 2012 Leela Barham	The Queen's English Defining the language of value based pricing in the United Kingdom and ultimately the world.
Pharmaceutical Executive December 1, 2006 Sarah Houlton	Global Report: Not So NICE A new manifesto by the Association of the British Pharmaceutical Industry is designed to improve drug access in the UK, where industry has worried for years about poor uptake of new medicines.
Pharmaceutical Executive October 1, 2008 Sarah Houlton	Open For Debate Tensions mount as stakeholders in the UK health industry attempt to work out drug cost problems.
Chemistry World March 17, 2014 Phillip Broadwith	UK to fast-track access to critical medicines Critically ill patients in the UK could receive new medicines before they are formally approved under a new scheme beginning in April.
Pharmaceutical Executive December 1, 2011	UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity.
Pharmaceutical Executive October 1, 2014 Leela Barham	The Gate Keeper Dr. David Haslam, Chair of the UK's National Institute of Health and Care Excellence, discusses what the quantitative calculations of value mean to patient access in today's messy world of real-time medicine.
Chemistry World July 2010	Meeting Mr NICE guy Bibiana Campos-Seijo meets the chief executive of the National Institute for Health and Clinical Excellence, Sir Andrew Dillon
Pharmaceutical Executive January 1, 2013 William Looney	The Permanent Campaign Promoting the merits of private-sector drug innovation is no easy task; just ask the UK's Office of Health Economics, with a record 50 years of engagement around the hard policy questions that ultimately drive success in the pharmaceutical marketplace.
Pharmaceutical Executive February 1, 2007 Sarah Houlton	Global Report: Under One Roof The UK government is planning to set up a single body to oversee all health research in universities and hospitals - and to facilitate partnerships between government agencies and industry.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
Chemistry World March 4, 2013 Andy Extance	UK considers patent rule change for trials The UK has announced plans to amend aspects of its patent law that may be encouraging pharma companies to run their clinical trials in other countries.
Pharmaceutical Executive May 1, 2005 Sarah Houlton	Global Report: Iron Fist The United Kingdom is hardening its stance on pharma industry issues.
The Motley Fool December 30, 2010 Brian Orelli	This NICE Deal Could Foreshadow 2011 Value-based pricing is coming. The only way to encourage lower drug costs is to get the end user to pay the cost directly.
Chemistry World January 3, 2013 Sarah Houlton	2012 pharma industry roundup It may have been a relatively quiet year in terms of mergers and acquisitions, but the pharma industry nonetheless made plenty of headlines in 2012.
Chemistry World December 8, 2011 Maria Burke	Government Launches UK Life Sciences Strategy Prime minister David Cameron has announced a package of measures designed to boost the UK's life sciences industry.
Pharmaceutical Executive June 1, 2007 Sarah Houlton	Global Report: Single-Source Supply Pfizer's move to consolidate its drug supply chain in the United Kingdom may signal safer - but more expensive - drugs.
Chemistry World October 8, 2010 Sarah Houlton	U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness.
Pharmaceutical Executive July 3, 2007 Sarah Houlton	Global Report: Five-Year Survivor: European Edition The UK government's attitude seems to be that oncology treatments are hugely expensive -- and that too much of the National Health Service budget is vanishing into the pockets of drug companies. Will cancer networks fill the gap?
Pharmaceutical Executive April 1, 2012 Feam & Lagus	Providing Access Now While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help.
Chemistry World May 4, 2006 Katharine Sanderson	Cancer Charity Takes on Shelved Drugs Cancer Research UK, and its commercial arm, Cancer Research Technology have launched a clinical development partnership scheme to sweep up drug candidates that pharmaceuticals companies have deprioritized for not showing enough commercial promise.
Pharmaceutical Executive January 21, 2014 Comer & Upton	Pharm Exec's Annual Industry Outlook 2014 For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive; muddling through is so yesterday.
Chemistry World September 5, 2014 Emma Stoye	Servier to appear in adverts over lack of transparency European pharma group Servier Laboratories is to appear in adverts for breaching the Association of the British Pharma Industry code of practice by failing to publish clinical trial results.
Chemistry World May 2006 Bea Perks	Editorial: Generics in the Dock The manufacturers of generic medicines in the U.K. must work harder to guard their good reputation. Or perhaps, manufacturers of generic medicines must work harder to counter their bad reputation.
Pharmaceutical Executive June 1, 2014 O'Connor et al.	Challenges to the Specialty Business Model New constraints require new solutions. Innovative, value-based pricing models will be critical to securing reimbursement and continued market access of high-price drugs.
Pharmaceutical Executive November 1, 2005 Sarah Houlton	Global Report: Drug Evaluation in the UK The availability of new medicines has been thrown into the limelight once more, with UK's National Institute for Health and Clinical Excellence being called upon to make dramatic improvements to the speed at which it carries out evaluations.
Pharmaceutical Executive July 1, 2012 Ben Comer	John Lechleiter on PhRMA and Innovation Eli Lilly CEO John Lechleiter on his agenda as incoming chairman of PhRMA, US healthcare reform, the euro crisis, and the small problem, of innovation.
Chemistry World April 23, 2013 Emma Stoye	Invest in research or be left behind, UK academies warn The UK's four national academies have called on the government to increase investment in research over the next decade or risk being overtaken by international competitors.
Chemistry World May 25, 2011 Sarah Houlton	Cost-cutting will stifle UK innovation The UK government's cost-cutting policies are in danger of stifling innovation, according to a report from The Work Foundation.
Chemistry World September 7, 2015	Cancer Drugs Fund axes 23 treatments The Cancer Drugs Fund, which covers the cost of some cancer treatments that are not currently available on the National Health Service, has cut 23 treatments -- involving 16 drugs.
Chemistry World December 4, 2012 Andrew Turley	Drug R&D costs rising Inventing a new drug costs an enormous amount of money. It's part of the reason why the pharma industry is struggling to fill its pipelines. But we'd like to think that -- however slowly -- that cost is coming down. Unfortunately it isn't.
Pharmaceutical Executive September 1, 2011 Richard Barker	Innovating Around Innovation The former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science.
Pharmaceutical Executive September 1, 2005 Parker & Amar	Building Blockbusters The most lucrative new drugs are often less glamorous than first-in-class new molecular entities. And they are much less risky.
Pharmaceutical Executive December 1, 2010	The Sum of All His Parts: Career Reflections of Europe's Chief Drug Regulator The European Medicines Agency is a unique institution, pursuing a mandate shared with a complex web of national and regional groups, each able to place a distinctive imprint around the delicate task of certifying the safety and efficacy of new drugs.
Pharmaceutical Executive February 4, 2011 William Looney	The Night Stalkers: Keeping CEOs Awake in 2011 The consensus is that 2011 will be a bad year for Big Pharma. Let's inventory a few of the 'night stalkers -- issues that are likely to keep members of the C-suite awake beyond a sensible 'lights out' time.
Pharmaceutical Executive September 1, 2010	Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development.
Pharmaceutical Executive June 1, 2013 Julian Upton	Opening the Patent Box Are the answers to the UK pharma sector's problems to be found in the government's new "Patent Box," which introduces a lower rate of corporation tax on profits generated from UK-owned intellectual property.
Knowledge@Wharton	Selling Life-Saving Drugs to Poorer Countries: At What Cost? Should rich countries pay more for drugs than less developed nations? This system of differential pricing makes sense on social-justice and economic grounds, but it is difficult to administer in the real world, some experts say.
Chemistry World December 22, 2011 Sarah Houlton	Pharma braces for patent cliff impact It remains to be seen quite how far Lipitor sales will fall. Ranbaxy has six months of exclusivity for generic competition.
Chemistry World December 17, 2015 Sarah Houlton	Pills, prices and politics Pharmaceutical pricing has been a hot topic in 2015, with the drugs bill continuing to rise as costly new treatments reach the market.
Chemistry World November 28, 2008 Matt Wilkinson	EU claims pharma delaying tactics cost 3 billion euros Pharmaceutical manufacturers have been criticised by the EU competition commission for slowing the entry of generic medicines to the market.
Pharmaceutical Executive September 1, 2012 Stan Bernard	The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model.
Pharmaceutical Executive January 1, 2006 Sarah Houlton	Global Report: The UK's New Code of Conduct Pharma companies' relationships with doctors are being tightened in the United Kingdom, after a major overhaul of the Association of the British Pharmaceutical Industry's Code of Practice.